| Protocol #
| Protocol Title
| CIRB Initial Review Date
| Group Activation Date
| Expiration Date
|
ACOSOG-Z1031
Lead Group: ACOSOG
Participating Groups:
ACOSOG
|
"A Randomized Phase III Trial Comparing 16 to 18 Weeks of Neoadjuvant Exemestane (25 mg daily), Letrozole (2.5 mg), or Anastrozole (1 mg) in Postmenopausal Women with Clinical Stage II and III Estrogen Receptor Positive Breast Cancer." |
7/19/2004 |
1/9/2006 |
7/4/2008 |
ACOSOG-Z1041
Lead Group: ACOSOG
|
"A Randomized Phase III Trial Comparing a Neoadjuvant Regimen of FEC-75 Followed By Paclitaxel Plus Trastuzumab With a Neoadjuvant Regimen of Paclitaxel Plus Trastuzumab Followed by FEC-75 Plus Trastuzumab in Patients with Palpable and Operable Breast Cancer" |
12/1/2006 |
7/2/2007 |
11/1/2008 |
ACOSOG-Z4032
Lead Group: ACOSOG
|
A Randomized Phase III Study of Sublobar Resection Versus Sublobar Resection Plus Brachytherapy in High-Risk Patients With Non-Small Cell Lung Cancer (Nsclc), 3cm or Smaller
|
4/19/2004 |
7/15/2005 |
5/1/2009 |
ACOSOG-Z9031
Lead Group: ACOSOG
Participating Groups:
CTSU RTOG
|
A Phase III Randomized Study of Preoperative Radiation Plus Surgery Versus Surgery Alone for Patients with Retroperitoneal Sarcomas (RPS) **COMPLETED (No Further Activity is being Conducted), as of February 27, 2006** |
4/19/2004 |
8/23/2004 |
|
CALGB-100104-ECOG 100104
Lead Group: CALGB
|
A Phase III Randomized Double-Blind Study of Maintenance Therapy with CC-5013 (NSC # 703813, IND# 70116) or Placebo Following Autologous Stem Cell Transplantation for Multiple Myeloma |
6/21/2004 |
12/15/2004 |
5/1/2009 |
CALGB-10201
Lead Group: CALGB
Participating Groups:
CTSU
|
A Phase III Study of Daunorubicin and Cytarabine +\- G3139 (GenasenseTM, Oblimersen Sodium, NSC #683428, IND #58842), A BCL2 Antisense Oligodeoxynucleotide, in Previously Untreated Patients with Acute Myeloid Leukemia (AML) > 60 Years
**Permanently Closed to New Patient Accrual - Effective Friday, October 20, 2006 at 5pm ET** |
9/15/2003 |
12/15/2003 |
1/13/2009 |
CALGB-10501
Lead Group: CALGB
|
A Phase III Intergroup CLL Study of Asymptomatic Patients with Untreated Chronic Lymphocytic Leukemia Patients Randomized to Early Intervention Versus Observation with Later Treatment in the High Risk Genetic Subset with IgVh Unmutated Disease |
3/19/2007 |
1/15/2008 |
2/18/2009 |
CALGB-10603
Lead Group: CALGB
|
A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) (IND # TBD) or Placebo in Newly Diagnosed Patients < 60 Years of Age with FLT3 Mutated Acute Myeloid Leukemia (AML) |
2/22/2008 |
4/1/2008 |
2/21/2009 |
CALGB-140503
Lead Group: CALGB
|
A Phase III Randomized Trial of Lobectomy versus Sublobar Resection for Small (< 2 Cm) Peripheral Non-Small Cell Lung Cancer |
2/12/2007 |
6/15/2007 |
12/6/2008 |
CALGB-30102
Lead Group: CALGB
Participating Groups:
CTSU SWOG
|
Phase III Comparison of Catheter Based Therapy of Pleural Effusions in Cancer Patients (Optimal Pleural Effusion Control, OPEC) **Closed to Accrual by CALGB - Effective December 28, 2004 at 5pm ET**
|
1/22/2002 |
5/15/2002 |
1/22/2009 |
CALGB-30610
Lead Group: CALGB
|
Phase III Comparison of Thoracic Radiotherapy Regimens with Cisplatin and Etoposide in Limited Small Cell Lung Cancer |
11/11/2007 |
3/21/2008 |
1/31/2009 |
CALGB-40101
Lead Group: CALGB
Participating Groups:
CTSU ECOG NCCTG SWOG
|
Cyclophosphamide and Doxorubicin (Ca) (4 Vs 6 Cycles) Versus Paclitaxel (4 Vs 6 Cycles) as Adjuvant Therapy for Women with 0-3 Positive Axillary Lymph Nodes: A 2x2 Factorial Phase III Study |
4/15/2002 |
5/15/2002 |
7/5/2008 |
CALGB-40302
Lead Group: CALGB
Participating Groups:
CALGB
|
"Endocrine Therapy With or Without Inhibition Of EGF And HER2 Growth
Factor Receptors: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of
Fulvestrant with or without Lapatinib (GW572016) For Postmenopausal Women With Hormone
Receptor Positive Advanced Breast Cancer" |
2/20/2001 |
9/15/2006 |
10/4/2008 |
CALGB-49907
Lead Group: CALGB
Participating Groups:
CTSU ECOG NCCTG NCIC-CTG SWOG
|
A Randomized Trial of Adjuvant Chemotherapy with Standard Regimens, Cyclophosphamide, Methotrexate and Fluorouracil-'CMF' or Doxorubicin and Cyclophosphamide-'AC', Versus Capecitabine in Women 65 Years and Older with Node Positive or Node Negative Stage Breast Cancer **Permanently Closed to New Patient Accrual - Effective Friday, December 29, 2006 at 5pm ET** |
8/20/2001 |
9/15/2001 |
2/21/2009 |
CALGB-50303
Lead Group: CALGB
|
Phase III Randomized Study of R-Chop V. Dose-Adjusted Epoch-R with Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas |
10/18/2004 |
5/2/2005 |
9/6/2008 |
CALGB-70301
Lead Group: CALGB
Participating Groups:
CALGB
|
"Quality of Life, Employment and informal Care Cost Analysis in Women Receiving Adjuvant Chemotherapy for Node-Negative Breast Cancer: Companion to 40101" |
6/20/2005 |
10/15/2005 |
11/18/2008 |
CALGB-80101
Lead Group: CALGB
Participating Groups:
CTSU ECOG NCCTG NCIC-CTG RTOG SWOG
|
A Phase III Intergroup Trial of Adjuvant Chemoradiation After Resection of Gastric or Gastroesophageal Adenocarcinoma |
8/19/2002 |
12/15/2002 |
4/20/2009 |
CALGB-80203
Lead Group: CALGB
Participating Groups:
CTSU
|
A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with and without Cetuximab (C225) for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum **Permanently Closed to new patient accrual - Effective January 15, 2005** |
8/18/2003 |
12/15/2003 |
8/2/2008 |
CALGB-80303
Lead Group: CALGB
Participating Groups:
CTSU
|
A Randomized Phase III Trial of Gemcitabine Plus Bevacizumab (NSC #704865 IND# 7921) versus Gemcitabine Plus Placebo in Patients with Advanced Pancreatic Cancer **Closed to Accrual by CALGB - Effective April 14, 2006 at 5pm ET**
|
4/19/2004 |
6/15/2004 |
8/2/2008 |
CALGB-90104
Lead Group: CALGB
Participating Groups:
CTSU ECOG
|
A Randomized Phase III Study Comparing Sequential Chemotherapy (AG-TP) to Cisplatin and Gemcitabine as Adjuvant Treatment after Cyctectomy for Transitional Cell Carcinoma of the Bladder **Closed to Accrual by CALGB on July 15, 2005** |
6/16/2003 |
3/15/2004 |
8/23/2008 |
CALGB-90202
Lead Group: CALGB
Participating Groups:
CTSU
|
A Randomized Double-Blind, Placebo-Controlled Phase III Study of Early Versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men with Prostate Cancer Metastatic to Bone. |
4/14/2003 |
1/15/2004 |
8/2/2008 |
CALGB-90203
Lead Group: CALGB
Participating Groups:
CALGB
|
"A Randomized Phase III Study of Neo-adjuvant Docetaxel and Androgen Deprivation prior to Radical Prostatectomy versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer" |
10/6/2005 |
12/15/2006 |
8/2/2008 |
CALGB-90206
Lead Group: CALGB
Participating Groups:
CTSU ECOG NCIC CTG
|
A Randomized Phase III Trial of Interferon Alfa-2B or Interferon Alfa-2B Plus Bevacizumab in Patients with Advanced Renal Carcinoma **Will be Permanently Closed to New Patient Accrual Effective Friday, July 1, 2005, at 5:00 pm ET** |
6/16/2003 |
10/1/2003 |
9/5/2008 |
CALGB-90401
Lead Group: CALGB
Participating Groups:
CTSU
|
A Randomized Double-Blinded Placebo Controlled Phase III Trial Comparing Docetaxel and Prednisone With and Without Bevacizumab (IND #7921, NSC #704865) in Men with Hormone Refractory Prostate Cancer
**Closed To Patient Accrual - Effective December 21, 2007 at 5pm EST** |
10/18/2004 |
4/15/2005 |
8/2/2008 |
CALGB-SWOG-C80405
Lead Group: CALGB
|
"A Phase III Trial of Irinotecan/5-Fu/Leucovorin or Oxaliplatin/5-Fu/Leucovorin with Bevacizumab, Or Cetuximab (C225), Or With The Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum" |
6/20/2005 |
9/15/2005 |
12/6/2008 |
COG-AALL0331
Lead Group: COG
|
Standard Risk B-precursor Acute Lymphoblastic Leukemia **Temporarily Closed to
Accrual by COG - Effective May 2, 2008** |
1/13/2005 |
4/11/2005 |
7/11/2008 |
COG-AALL03B1
Lead Group: COG
Participating Groups:
COG
|
Classification of Acute Lymphoblastic Leukemia **Temporary Partial Closure to Accrual for Non-Infant B-precursor ALL
Patients and T-cell Patients by COG - Effective May 5, 2008**
**Temporary Suspension of Enrollment of High-Risk B-precursor Patients by COG - Effective April 25, 2008** |
1/13/2005 |
12/29/2003 |
7/11/2008 |
COG-AALL03N1
Lead Group: COG
Participating Groups:
COG
|
"Understanding the Ethnic and Racial Differences in Survival in Children with Acute Lymphoblastic Leukemia" |
11/22/2004 |
5/30/2005 |
10/10/2008 |
COG-AALL0433
Lead Group: COG
|
"Intensive Treatment For Intermediate-Risk Relapse Of Childhood B-Precursor Acute Lymphoblastic Leukemia (All): A Randomized Trial Of Vincristine Strategies" |
1/26/2006 |
3/26/2007 |
9/26/2008 |
COG-AALL0434
Lead Group: COG
Participating Groups:
COG
|
"Intensified Methotrexate, Nelarabine (Compound 506U78; IND # 52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia" **Temporarily Closed to
Accrual by COG - Effective May 2, 2008**
**Enrollment Suspended for Patients with Down Syndrome by COG - Effective February 20, 2008**
|
2/23/2006 |
1/15/2007 |
8/22/2008 |
COG-AALL05B1
Lead Group: COG
|
"A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens." |
4/13/2006 |
9/25/2006 |
4/9/2009 |
COG-AALL0631
Lead Group: COG
|
A Phase III Study of Risk Directed Therapy for Infants with Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431; NSC#617807) |
7/12/2007 |
1/14/2008 |
7/11/2008 |
COG-AALL06N1
Lead Group: COG
Participating Groups:
COG
|
A Study of Neurocognitive Function in Children Treated for ALL. **Temporary Closure - Effective April 3, 2008 ** |
10/26/2006 |
1/29/2007 |
8/22/2008 |
COG-AAML0431
Lead Group: COG
|
"The Treatment of Down Syndrome Children with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Under the age of 4 Years." |
1/26/2006 |
3/26/2007 |
2/13/2009 |
COG-AAML0523
Lead Group: COG
|
"A Phase II Study of CLOLAR® (Clofarabine, IND# 73,789) in Combination with Cytarabine in Pediatric Patients with Refractory/Relapsed Leukemia." **Temporary Closure - Effective March 28, 2008 ** |
4/13/2006 |
3/12/2007 |
11/7/2008 |
COG-AAML0531
Lead Group: COG
|
"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg®) Combined with Conventional
Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children,Adolescents, and Young Adults" |
2/23/2006 |
8/14/2006 |
9/26/2008 |
COG-AAML05P1
Lead Group: COG
|
Killer Immunoglobulin-like Receptor (KIR) Incompatible Unrelated Donor Hematopoietic Cell Transplantation (HCT) for Refractory and Relapsed Acute Myelogenous Leukemia (AML) and newly diagnosed AML with monosomy 7 or -5/5qin Children |
3/8/2007 |
1/21/2008 |
12/20/2008 |
COG-AAML06P1
Lead Group: COG
|
"A Pilot Study of Lestaurtinib (CEP-701) in Combination with Chemotherapy in Young Patients with Relapsed or Refractory Acute Myeloid Leukemia" |
12/14/2006 |
6/11/2007 |
12/12/2008 |
COG-AAML07P1
Lead Group: COG
Participating Groups:
COG
|
A Phase II Pilot Study of Bortezomib (PS-341, Velcade) Combined with Reinduction Chemotherapy in Children and Young Adults with Recurrent, Refractory or Secondary Acute Myeloid Leukemia |
11/8/2007 |
4/21/2008 |
11/7/2008 |
COG-ABTR04B1
Lead Group: COG
|
"Establishing Continuous Cell Lines and Xenografts from Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies" |
1/26/2006 |
3/5/2007 |
9/26/2008 |
COG-ACCL04C2
Lead Group: COG
|
Randomized Study of Electroacupuncture Treatment for Delayed Chemotherapy-induced Nausea and Vomiting in Patients with Pediatric Solid Tumors (02-AT-0172) |
11/22/2004 |
12/12/2005 |
8/8/2008 |
COG-ACCL05C1
Lead Group: COG
|
"A Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy" |
6/22/2006 |
2/5/2007 |
12/12/2008 |
COG-ACCL0631
Lead Group: COG
|
Impact of Obesity on the Pharmacokinetics of Anticancer Therapy in Children with High Risk Acute Lymphoblastic Leukemia - A Group-wide Non-Therapeutic Study |
5/10/2007 |
3/24/2008 |
8/22/2008 |
COG-ACCRN07
Lead Group: COG
|
Childhood Cancer Research Network: Protocol for Registration and Consent Procedures of the Children's Oncology Group |
3/8/2007 |
12/24/2007 |
8/22/2008 |
COG-ACNS0221
Lead Group: COG
|
"A Phase II Study of Conformal Radiotherapy In Patients with Low-Grade Gliomas; A Groupwide Phase II Study" |
3/10/2005 |
11/28/2005 |
8/8/2008 |
COG-ACNS0222
Lead Group: COG
|
"A Phase II Study of Motexafin-Gadolinium (NSC 695238, IND #55583) and Involved Field Radiation Therapy for Intrinsic Pontine Glioma of Childhood." |
4/24/2006 |
6/4/2007 |
12/12/2008 |
COG-ACNS0232
Lead Group: COG
Participating Groups:
COG
|
"Radiotherapy Alone vs. Chemotherapy Followed by Response-based Radiotherapy for Newly Diagnosed Primary CNS Germinoma: A Phase III Group-Wide Study" |
9/8/2005 |
1/29/2007 |
3/12/2009 |
COG-ACNS0332
Lead Group: COG
|
"Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients." |
4/24/2006 |
3/26/2007 |
1/9/2009 |
COG-ACNS0334
Lead Group: COG
|
"A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children < 36 months Old with Intensive Induction Chemotherapy with Methotrexate Followed by Consolidation with Stem Cell Rescue vs. the Same Therapy Without Methotrexate" |
1/26/2006 |
7/24/2007 |
9/9/2008 |
COG-ACNS0423
Lead Group: COG
Participating Groups:
COG
|
A Phase II Study of Concurrent Radiation and Temozolomide Followed by Temozolomide and CCNU in the Treatment of Children with High Grade Glioma **Closed to Accrual by COG - Effective October 26, 2007**
|
1/13/2005 |
3/21/2005 |
7/11/2008 |
COG-ADVL0221
Lead Group: COG
|
"A Phase II Study of ET-743 in Children with Recurrent Sarcomas"
|
2/24/2005 |
1/28/2008 |
1/20/2009 |
COG-ADVL0524
Lead Group: COG
|
"Phase II Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Children and Young Adults with Refractory Solid Tumors " **Closed to Accrual by COG - Effective October 26, 2007** |
11/10/2005 |
4/24/2006 |
9/26/2008 |
COG-ADVL0525
Lead Group: COG
|
"A Phase II Study of Pemetrexed in Children with Recurrent Malignancies." |
10/12/2006 |
9/3/2007 |
7/16/2008 |
COG-ADVL06B1
Lead Group: COG
|
A Pharmacokinetic-Pharmacodynamic-Pharmacogenetic Study of Actinomycin-D and Vincristine in Children with Cancer - A Groupwide Non-Therapeutic Study |
4/12/2007 |
2/11/2008 |
2/24/2009 |
COG-AEWS0521
Lead Group: COG
Participating Groups:
COG
|
A Randomized Phase II Study of Bevacizumab (NSC 704865, BB-IND# 7921) Combined with Vincristine, Topotecan and Cyclophosphamide in Patients with First Recurrent Ewing Sarcoma |
11/9/2006 |
2/25/2008 |
9/9/2008 |
COG-AEWS0531
Lead Group: COG
|
"A Phase III Randomized Trial of Adding Vincristine-topotecan-cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma: A Groupwide Phase III Study." |
1/12/2006 |
2/25/2008 |
9/9/2008 |
COG-AEWS0621
Lead Group: COG
Participating Groups:
COG
|
"Phase II Trial of Intermediate-Dose Cytarabine to Modulate EWS/FLI for Children and Young Adults with Recurrent or Refractory Ewing Sarcoma" **Closed to Accrual by COG - Effective May 2, 2008** |
10/12/2006 |
5/7/2007 |
7/10/2008 |
COG-AEWS07B1
Lead Group: COG
|
A COG Study for Collecting and Banking Ewing Sarcoma Specimens |
6/14/2007 |
2/4/2008 |
3/10/2009 |
COG-AEWS07P1
Lead Group: COG
|
A Pilot Study of Chemotherapy Intensification by Adding Vincristine, Topotecan and Cyclophosphamide to Standard Chemotherapy Agents with an Interval Compression Schedule in Newly Diagnosed Patients with Localized Ewing Sarcoma Family of Tumors |
8/9/2007 |
3/9/2008 |
8/8/2008 |
COG-AGCT0521
Lead Group: COG
|
Treatment of Recurrent or Resistant Pediatric Malignant Germ Cell Tumors with Paclitaxel, Ifosfamide and Carboplatin |
11/30/2006 |
11/5/2007 |
10/15/2008 |
COG-AHOD03P1
Lead Group: COG
|
"Treatment of Children with Newly-Diagnosed Low Stage Lymphocyte Predominant Hodgkin Disease (LPHD); A Groupwide Pilot Study" |
3/10/2005 |
1/2/2006 |
8/8/2008 |
COG-AHOD0431
Lead Group: COG
|
"A Phase III Study for the Treatment of Children and Adolescents With Newly Diagnosed Low Risk Hodgkin Disease" |
4/28/2005 |
2/13/2006 |
8/22/2008 |
COG-AHOD04B1
Lead Group: COG
Participating Groups:
COG
|
"Hodgkin Disease (HD) Banking Study" |
6/8/2006 |
10/23/2006 |
2/13/2009 |
COG-AHOD0521
Lead Group: COG
Participating Groups:
COG
|
A Phase II Study of Bortezomib (Velcade, PS-341, IND #58443) in Combination with Ifosfamide/Vinorelbine in Pediatric Patients and Young Adults with Refractory/Recurrent Hodgkin Disease |
6/22/2006 |
1/16/2007 |
2/13/2009 |
COG-ANBL00B1
Lead Group: COG
|
Neuroblastoma Biology Studies |
1/27/2005 |
10/25/2005 |
7/11/2008 |
COG-ANBL00P3
Lead Group: COG
|
Phase III Randomized Trial of Intravenous Gammaglobulin Therapy for Patients with Neuroblastoma Associated Opsoctonus-Myoclonus-Ataxia Syndrome Treated with Chemotherapy and Prednisone |
1/27/2005 |
9/21/2005 |
10/10/2008 |
COG-ANBL0421
Lead Group: COG
|
"A Phase II Study of Irinotecan + Temozolomide in Children with Recurrent Neuroblastoma" **Stratum 1 Closed to Enrollment by COG - Effective April 11, 2008** |
7/14/2005 |
4/24/2006 |
4/9/2009 |
COG-ANBL0531
Lead Group: COG
Participating Groups:
COG
|
"Response and Biology-Based Therapy for Intermediate-Risk Neuroblastoma." |
11/30/2006 |
10/8/2007 |
1/9/2009 |
COG-ANBL0532
Lead Group: COG
|
Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma |
3/8/2007 |
11/5/2007 |
1/9/2009 |
COG-ANHL04B1
Lead Group: COG
|
Rare and Cutaneous Non-Hodgkin Lymphoma Registry |
1/13/2005 |
5/30/2005 |
7/11/2008 |
COG-AOST0331
Lead Group: COG
|
A Randomized Trial of the European and American Osteosarcoma Study Group to Optimize Treatment Strategies for Resectable Osteosarcoma Based on Histological Response to Pre-Operative Chemotherapy |
1/27/2005 |
11/14/2005 |
7/11/2008 |
COG-AOST06B1
Lead Group: COG
|
¿A Children's Oncology Group Protocol for Collecting and Banking Osteosarcoma Specimens¿ |
12/28/2006 |
2/4/2008 |
10/11/2008 |
COG-ARAR0331
Lead Group: COG
|
"Treatment of Childhood Nasopharyngeal Carcinoma with Neoadjuvant Chemotherapy and Concomitant Chemoradiotherapy: A Groupwide Phase III Study" |
3/10/2005 |
2/20/2006 |
8/8/2008 |
COG-ARAR0332
Lead Group: COG
Participating Groups:
COG
|
"Treatment of Adrenocortical Tumors with Surgery plus Lymph Node Dissection and Multiagent Chemotherapy; A Groupwide Phase III Study" |
3/10/2005 |
9/18/2006 |
12/12/2008 |
COG-AREN0321
Lead Group: COG
|
"Treatment of High Risk Renal Tumors: A Groupwide Phase II Study" **Enrollment Suspended for Stratum 20 by COG - Effective September 11, 2007**
|
7/28/2005 |
6/19/2006 |
8/22/2008 |
COG-AREN03B2
Lead Group: COG
|
"Renal Tumors Classification, Biology, and Banking Study" |
7/28/2005 |
2/27/2006 |
1/9/2009 |
COG-AREN0532
Lead Group: COG
Participating Groups:
COG
|
"Treatment for Very Low, Low and Standard Risk Favorable Histology Wilms Tumor." |
4/13/2006 |
10/30/2006 |
11/7/2008 |
COG-AREN0533
Lead Group: COG
|
"Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumor" |
4/13/2006 |
2/26/2007 |
12/12/2008 |
COG-ARET0231
Lead Group: COG
|
A Single Arm Trial of Systemic and Subtenon Chemotherapy for Groups C and D Intraocular Retinoblastoma: A Phase III Limited Institution Study |
10/6/2005 |
4/16/2007 |
1/9/2009 |
COG-ARET0321
Lead Group: COG
|
"A Trial of Intensive Multi-Modality Therapy for Extra-Ocular Retinoblastoma." |
1/12/2006 |
2/4/2008 |
1/20/2009 |
COG-ARET0331
Lead Group: COG
|
"Trial of systemic neoadjuvant chemotherapy for Group B intraocular retinoblastoma; A Phase III Limited Institution Study" |
2/10/2005 |
12/26/2005 |
8/8/2008 |
COG-ARET0332
Lead Group: COG
|
"Adjuvant Therapy for Patients with Unilateral Retinoblastoma with High Risk Features on Histopathologic Examination; A Groupwide Phase III Study " |
2/24/2005 |
12/12/2005 |
8/22/2008 |
COG-ARST0332
Lead Group: COG
Participating Groups:
COG
|
"Risk-Based Treatment for Pediatric Non-Rhabdomyosarcoma
Soft Tissue Sarcomas (NRSTS):
A Groupwide Phase III Study |
3/23/2006 |
2/5/2007 |
10/10/2008 |
COG-ARST03P1
Lead Group: COG
|
"A Pilot Phase II Study for Children with Infantile Fibrosarcoma; A Groupwide Phase II Study" **Closed to Accrual - Effective January 19, 2007 at 5 PM ET** |
2/24/2005 |
7/22/2005 |
3/16/2009 |
COG-ARST0431
Lead Group: COG
Participating Groups:
COG
|
"Intensive Multi-Agent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide (IE) and Vincristine/Doxorubicin/Cyclophosphamide (VDC) for Patients with High-Risk Rhabdomyosarcoma: A Groupwide Phase III Study" **Closed to Accrual by COG - Effective March 17, 2008 5 p.m. EST** |
12/8/2005 |
7/17/2006 |
7/12/2008 |
COG-ARST0531
Lead Group: COG
Participating Groups:
COG
|
Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) versus VAC Alternating with Vincristine and Irinotecan (VI) for Patients with Intermediate-Risk Rhabdomyosarcoma (RMS) |
1/12/2006 |
12/26/2006 |
8/8/2008 |
COG-ASCT0431
Lead Group: COG
|
"A Randomized Trial of Sirolimus-Based Graft versus Host Disease Prophylaxis After Hematopoietic Stem Cell Transplantation in Relapsed ALL" |
3/23/2006 |
3/19/2007 |
1/9/2009 |
COG-ASCT0631
Lead Group: COG
|
"A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation." |
10/26/2006 |
12/31/2007 |
3/31/2009 |
COG-D9902
Lead Group: COG
|
"A COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol." |
12/8/2005 |
2/20/2006 |
7/11/2008 |
ECOG-E1105
Lead Group: ECOG
Participating Groups:
ECOG
|
"A Randomized Phase III Double Blind Placebo-Controlled Trial of First Line Chemotherapy and Trastuzumab with or without Bevacizumab for Patients with HER-2/NEU Over-expressing Metastatic Breast Cancer" |
3/13/2007 |
11/9/2007 |
9/6/2008 |
ECOG-E1301
Lead Group: ECOG
Participating Groups:
ACOSOG CTSU NCIC CTG
|
A Phase III Randomized study of Adjuvant Biologic Therapy in Patients with Stages III/IV Head and Neck Squamous Cell Carcinoma **Closed to Accrual - Effective December 20, 2004 at 5pm ET** |
5/13/2002 |
2/21/2003 |
8/16/2008 |
ECOG-E1302
Lead Group: ECOG
|
Phase III Randomized, Placebo-Controlled Trial of Docetaxel Versus Docetaxel Plus Zd1839 ("Iressa") In Performance Status 2 Or Previously Treated Patients With Recurrent or Metastatic Head and Neck Cancer. **Partial closure: Arm C (step 2) has been permanently closed as of 8/22/07** |
2/9/2004 |
8/6/2004 |
7/15/2008 |
ECOG-E1505
Lead Group: ECOG
|
A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC) |
1/23/2006 |
6/1/2007 |
9/6/2008 |
ECOG-E1899
Lead Group: ECOG
Participating Groups:
CALGB CTSU SWOG
|
A Phase III Randomized Trial for Evaluating Second Line Hormonal Therapy (Ketoconazole/Hydrocortisone) versus Docetaxel/Estramustine Combination Chemotherapy on Progression Free Survival in Asymptomatic Patients with a Rising PSA after Hormonal Therapy for Prostate Cancer **Closed to Accrual - Effective December 28, 2004 at 5pm ET** |
7/15/2002 |
10/31/2002 |
10/4/2008 |
ECOG-E1900
Lead Group: ECOG
Participating Groups:
CTSU
|
A Phase III Trial in Adult Acute Myeloid Leukemia: Daunorubicin Dose-Intensification and Gemtuzumab-Ozogamicin Consolidation Therapy Prior to Autologous Stem Cell Transplantation
**Accrual Suspended as of Feb 1, 2008 - No new patients should be enrolled into this study**
**RE-OPENED TO ACCRUAL, as of April 29, 2008**
|
3/18/2002 |
12/16/2002 |
10/31/2008 |
ECOG-E1A00
Lead Group: ECOG
Participating Groups:
CTSU
|
A Randomized Phase III Trial of Thalidomide (NSC #66847) Plus
Dexamethasone Versus Dexamethasone in Newly Diagnosed Multiple Myeloma **Closed to Accrual - Effective April 18, 2003** |
11/13/2001 |
4/17/2002 |
11/5/2008 |
ECOG-E1A05
Lead Group: ECOG
|
"Randomized Phase III Trial of Consolidation Therapy with Bortezomib (Velcade) - Lenalidomide
(Revlimid) - Dexamethasone (VRD) versus Bortezomib (Velcade) - Dexamethasone (VD) for
Patients 2ith Multiple Myeloma Who Have Completed a Dexamethasone Based Induction Regimen" |
2/12/2007 |
9/6/2007 |
3/16/2009 |
ECOG-E1A06
Lead Group: ECOG
|
An Intergroup Phase III Randomized Controlled Trial Comparing Melphalan, Prednisone and Thalidomide (MPT) Versus Melphalan, Prednisone and Lenalidomide (Revlimid?) (MPR) in Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for High-Dose Therapy |
4/6/2007 |
2/29/2008 |
3/23/2009 |
ECOG-E1Y03
Lead Group: ECOG
|
Master Protocol for Pharmacogenetic and Genomic Studies
|
2/22/2005 |
9/15/2004 |
11/6/2008 |
ECOG-E2100
Lead Group: ECOG
Participating Groups:
CALGB CTSU NCCTG NCIC CTG NSABP SWOG
|
A Randomized Phase III Trial of Paclitaxel versus Paclitaxel plus Bevacizumab (rhuMAb VEGF) as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer **Closed to Accrual - Effective May 26, 2004** |
8/20/2001 |
12/21/2001 |
9/6/2008 |
ECOG-E2499
Lead Group: ECOG
|
Randomized Phase III Trial of Rituximab (NSC #687451) and Autologous Stem Cell Transplantation for B Cell Diffuse Large Cell Lymphoma **CLOSED TO ACCRUAL - Effective 5:00 pm EST on May 26, 2006** |
9/17/2002 |
3/27/2003 |
1/3/2009 |
ECOG-E2603
Lead Group: ECOG
Participating Groups:
ECOG
|
A Double-Blind, Randomized, Placebo-Controlled Phase III Trial Of Carboplatin, Paclitaxel And Bay 43-9006 Versus Carboplatin, Paclitaxel And Placebo In Patients With Unresectable Locally Advanced Or Stage IV Melanoma
**CLOSED TO ACCRUAL - Effective 5:00 pm EST on Tuesday, April 22, 2008** |
9/13/2004 |
6/23/2005 |
4/3/2009 |
ECOG-E2805
Lead Group: ECOG
Participating Groups:
ECOG
|
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable REnal Carcinoma |
12/19/2005 |
4/24/2006 |
8/2/2008 |
ECOG-E2902
Lead Group: ECOG
Participating Groups:
CTSU SWOG
|
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission after Primary Induction Failure **CTSU Re-Activation Date: 2/7/08** |
11/17/2003 |
8/18/2004 |
12/6/2008 |
ECOG-E3200
Lead Group: ECOG
Participating Groups:
CTSU
|
Phase III Trial of Bevacizumab, Oxaliplatin, Fluorouracil and Leucovorin versus Oxaliplatin, Fluorouracil and Leucovorin versus Bevacizumab Alone in Previously Treated Patients with Advanced Colorectal Cancer **Closed to Accrual - Effective April 28, 2003 at 5pm ET** |
7/16/2001 |
10/30/2001 |
9/6/2008 |
ECOG-E3201
Lead Group: ECOG
Participating Groups:
CALGB CTSU NCCTG NSABP SWOG
|
Intergroup Randomized Phase III Study of Postoperative Irinotecan, 5-Fluorouracil and Leucovorin vs Oxaliplatin, 5-Fluorouracil and Leucovorin vs 5-Fluorouracil and Leucovorin for Patients with Stage II or III Rectal Cancer Receiving Either Preoperative Radiation and -Fluorouracil or Postoperative Radiation and 5-Fluorouracil **Accrual Closed Effective November 1, 2005**
|
2/17/2003 |
10/15/2003 |
1/13/2009 |
ECOG-E3805
Lead Group: ECOG
Participating Groups:
ECOG
|
"CHAARTED: ChemHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer" |
7/18/2005 |
7/28/2006 |
9/16/2008 |
ECOG-E3999
Lead Group: ECOG
|
A Randomized, Placebo-controlled, Double Blind, Trial of the Administration of the MDR Modulator, Zosuquidar Trihydrochloride (LY335979), During Conventional Induction and Post-Remission Therapy in Patients Greater than 60 Years of Age with Newly Diagnosed Acute Myeloid Leukemia, Refractory Anemia with Excess Blasts in Transformation or High-Risk Refractory Anemia with Excess Blasts
**Study closed to accrual 09/15/05**
**ECOG has Discontinued Activation of
any New Sites to this Study - Effective Immediately (4/19/05) **
|
5/13/2002 |
7/17/2002 |
8/2/2008 |
ECOG-E4201
Lead Group: ECOG
Participating Groups:
CTSU NCCTG NCIC CTG RTOG
|
A Randomized Phase III Study of Gemcitabine in Combination with Radiation Therapy Versus Gemcitabine Alone in Patients with Localized, Unresectable Pancreatic Cancer **Closed to Accrual on December 15, 2005** |
11/12/2002 |
4/10/2003 |
10/11/2008 |
ECOG-E4402
Lead Group: ECOG
Participating Groups:
CTSU
|
Randomized Phase III Trial Comparing Two Different Rituximab Dosing Regimens for Low Tumor Burden Patients with Indolent non-Hodgkin's Lymphoma |
7/21/2003 |
11/21/2003 |
9/6/2008 |
ECOG-E4599
Lead Group: ECOG
Participating Groups:
CALGB CTSU
|
A Randomized Phase II/III Trial of Paclitaxel plus Carboplatin with or without Bevacizumab (NSC #704865) in Patients with Advanced Non-squamous NSCLC **Study Closed to accrual by ECOG, Patients still on treatment - Effective 5:00pm EST April 7, 2004 ** |
6/18/2001 |
7/19/2001 |
8/19/2008 |
ECOG-E4A03
Lead Group: ECOG
Participating Groups:
CTSU
|
A Randomized Phase III Study of CC-5013 Plus Dexamethasone Versus CC-5013 Plus Low Dose Dexamethasone in Multiple Myeloma with Thalidomide Plus Dexamethasone Salvage Therapy for Non-Responders **Closed to Accrual by ECOG - Effective June 1, 2007 at 5pm ET**
|
5/17/2004 |
10/26/2004 |
9/6/2008 |
ECOG-E5103
Lead Group: ECOG
Participating Groups:
ECOG
|
"A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer" |
8/21/2006 |
11/2/2007 |
2/21/2009 |
ECOG-E5202
Lead Group: ECOG
Participating Groups:
ECOG
|
A Randomized Phase III Study Comparing 5-FU, Leucovorin, and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers |
9/20/2004 |
8/4/2005 |
1/31/2009 |
ECOG-E5204
Lead Group: ECOG
Participating Groups:
ECOG
|
Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil
and Leucovorin vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for
Patients with Stage II or III Rectal Cancer Receiving Pre-operative Chemoradiation |
12/2/2005 |
2/17/2006 |
4/3/2009 |
ECOG-E6201
Lead Group: ECOG
Participating Groups:
CALGB CTSU NCCTG
|
A Phase III, Randomized Study of Gemcitabine [fixed-dose rate infusion] and Oxaliplatin versus Gemcitabine [fixed-dose rate infusion] versus Gemcitabine [30-minute infusion] in Pancreatic Carcinoma **Closed to Accrual - Effective March 16, 2005 5:00 pm EST**
|
9/17/2002 |
2/22/2003 |
9/16/2008 |
ECOG-PACCT-1
Lead Group: ECOG
Participating Groups:
ECOG
|
"Program for the Assessment of Clinical Cancer Tests (PACCT-1):
Trial Assigning Individualized Options for Treatment: The Tailor Rx Trial" |
11/21/2005 |
4/7/2006 |
9/6/2008 |
GOG-0198
Lead Group: GOG
Participating Groups:
CTSU
|
A Randomized Study of Tamoxifen Versus Thalidomide (NSC # 66847) In Patients With Biochemical-Recurrence-Only Epithelial Ovarian Cancer, Cancer of the Fallopian Tube, and Primary Peritoneal Carcinoma After First Line Chemotherapy **Closed to Accrual - Effective July 30, 2007 at 5:00pm EST** |
3/18/2002 |
2/3/2003 |
7/15/2008 |
GOG-0204
Lead Group: GOG
|
A Randomized Phase III Trial of Paclitaxel Plus Cisplatin Versus Vinorelbine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Versus Topotecan Plus Cisplatin in Stage IVB, Recurrent, or Persistent Carcinoma of the Cervix **Closed to Accrual - Effective April 30, 2007 at 5:00pm EST** |
3/17/2003 |
5/27/2003 |
7/5/2008 |
GOG-0209
Lead Group: GOG
Participating Groups:
CTSU
|
Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF versus Carboplatin/Paclitaxel in Patients with Stage III & IV or Recurrent Endometrial Cancer.
**SUSPENSION OF ENTRY TO PATIENTS WITH PRIOR EXTERNAL RADIATION THERAPY, EFFECTIVE 7/23/2007 **
**RE-ENTRY OF SUBJECTS WITH PRIOR EXTERNAL RADIATION THERAPY, EFFECTIVE 2/11/2008** |
3/17/2003 |
8/25/2003 |
11/18/2008 |
GOG-0212
Lead Group: GOG
|
A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or Xyotax(TM) (CT-2103) (IND # 70177), versus No Treatment Until Documented Relapse in Women With Advanced Ovarian or Primary Peritoneal Cancer who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy |
1/7/2005 |
3/21/2005 |
8/2/2008 |
GOG-0213
Lead Group: GOG
|
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab (NSC #704865, IND #7921) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer |
6/1/2007 |
12/6/2007 |
8/2/2008 |
GOG-0218
Lead Group: GOG
|
A Phase III Trial Of Carboplatin And Paclitaxel Plus Placebo Versus Carboplatin And Pac |